Showcasing select automated instruments and capabilities at Society for Laboratory Automation and Screening Europe 2022 Conference and Exhibition in Dublin, Ireland
Molecular Devices, LLC., a leading provider of high-performance life science solutions, today introduced five ready-made workcells for Enzyme-linked immunosorbent assay (ELISA) workflows that offer automation capabilities ranging from entry level to advanced.
Automating labour-intensive plate-based assays increases walkaway time, throughput, and reproducibility by reducing the amount of common, repetitive, hands-on steps for researchers.
“The pandemic has taught us that walkaway time and automation are critical to keeping labs on track so that scientists can focus on more critical assay development challenges,” said Celeste Glazer, Vice President, Global Marketing and Product Management, Molecular Devices. “The ability to reallocate resources from laborious tasks to more innovative work is critical for accelerating lifesaving research and bringing more therapeutics to market.”
“Our new automated ELISA workcells offer five levels of automation, taking the hands-on work out of plate loading and advancing until manual intervention is almost entirely unnecessary. With this approach, we’re leveraging our extensive experience automating workflows to best support scientists wherever they are in their automation journey,” Glazer concluded.